


COMPLIMENTARY  
VIRTUAL SYMPOSIUM  
MARCH 3, 2023

# 1<sup>st</sup> Annual Symposium on **Advanced Therapeutics for Brain Metastasis**

Moving the Needle and Controversies  
at the Cutting Edge



Memorial Sloan Kettering  
Cancer Center

# Overview

**Memorial Sloan Kettering Cancer Center is excited to announce a new complimentary Brain Metastasis Symposium on Friday, March 3, 2023.**

This virtual Symposium will provide clinicians and translational scientists with updates on the latest developments in brain metastasis treatment and research, CNS-specific outcomes from molecular and traditional cancer histology viewpoints.

Recent evidence for brain metastasis activity will be highlighted for key medical targets (e.g. Her2, EGFR, KRAS, CDK, BRAF, and ALK), and leading experts will review brain metastasis prognosis across the cancers commonly resulting in this (lung, breast, and melanoma).

This Symposium is intended for neurosurgeons, radiation oncologists, neurologists and neuro-oncologists, physicians in training, and other allied health professionals who treat and manage patients with metastatic disease.

---

[mskcc.org/BrainMetsSymposium](https://mskcc.org/BrainMetsSymposium)  
[#MSKbrainmetsCME](https://twitter.com/MSKbrainmetsCME)

## Highlights of This Didactic and Case-Based Symposium

- Sessions on the **recent developments in local therapy**, a review of the role of **laser interstitial thermal therapy**, **brachytherapy**, and **external beam radiation** techniques.
- In recognition of the many complex treatment interactions imposed by multimodality treatment often necessary, a **'Key Controversies' session will speak to major areas of clinical difficulty**; for example: how to distinguish the recurrent disease from radiation necrosis on imaging studies, when to change therapy with CNS-only progressive disease, which leptomeningeal metastasis interventions are currently worthwhile, and special considerations regarding steroid use and radiation therapy for patients requiring immunotherapy.
- Key scientists will discuss promising **translational and clinical trial approaches** including targeting metastasis-initiating cells and window-of-opportunity studies.
- Given the special challenge of early detection, a dedicated session will cover **state-of-the-art molecular imaging techniques**, the evidence for/against **imaging surveillance in standard-risk cancers**, and the current state of **liquid biopsy**.
- A **roundtable discussion with participants from several centers** will share their experiences and best practices with multidisciplinary team care and discuss areas for improvement.
- Finally, a **multidisciplinary tumor board** will review multifaceted cases, highlighting the interplay of various treatment options.

There will be **ample opportunity for networking with speakers and other participants** in this virtual meeting.

## MSK Symposium Director



### **NELSON MOSS, MD**

Co-Director, Multidisciplinary Brain Metastasis Program  
Assistant Attending, Department of Neurosurgery

## MSK Symposium Co-Director



### **ADRIENNE A. BOIRE, MD, PHD**

Geoffrey Beene Junior Faculty Chair  
Associate Attending, Brain Tumor Service,  
Department of Neurology

## Invited Faculty

### **KATHRYN BEAL, MD**

Director of the Center for Brain Metastases  
Meyer Cancer Center at the Weill Cornell Medical Center

### **PRISCILLA BRASTIANOS, MD**

Director, Central Nervous System Metastasis Program  
Associate Professor of Medicine  
Harvard Medical School  
Massachusetts General Hospital

### **VERONICA CHIANG, MD**

Professor, Yale University School of Medicine  
Departments of Neurosurgery and Therapeutic Radiology  
Assistant Dean for MD Admissions, Yale University School of Medicine  
Vice-Chair of Academic Affairs, Dept of Neurosurgery  
Director, Yale New Haven Hospital Gamma Knife Program  
Director, Yale Multidisciplinary Brain Metastasis Program

### **MICHAEL DAVIES, MD, PHD**

Professor and Chair, Department of Melanoma Medical Oncology  
Professor, Translational Molecular Pathology, Genomic Medicine, Systems Biology  
Anne and John Mendelsohn Chair in Cancer Research  
The University of Texas MD Anderson Cancer Center

### **PETER FECCI, MD**

Director, Duke Center for Brain and Spine Metastasis  
Director, Brain Tumor Immunotherapy Program  
Director, Surgical Neuro-oncology  
Duke Cancer Center

### **NANCY LIN, MD**

Associate Chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers  
Director, Metastatic Breast Cancer Program  
Director, Program for Patients with Breast Cancer Brain Metastases  
Senior Physician  
Associate Professor of Medicine, Harvard Medical School

**SARAH SAMMONS, MD**

Associate Director, Metastatic Breast Cancer Program  
Dana-Farber Cancer Institute

**HUSSEIN TAWBI, MD, PHD**

Deputy Chair, Department of Melanoma Medical Oncology  
Co-Director, MD Anderson Brain Metastasis Clinic  
The University of Texas MD Anderson Cancer Center

**MANUEL VALIENTE, PHD**

Principal Investigator  
CNIO

**MIN YU, MD, PHD**

Associate Professor, Department of Pharmacology  
University of Maryland School of Medicine

**MSK Faculty****BRANDON IMBER, MD, MA**

Assistant Attending, Department of Radiation Oncology

**BOB T. LI, MD, PHD, MPH**

Physician Ambassador to China and Asia-Pacific, Bobst International Center  
Co-Director, Thoracic Liquid Biopsy Program  
Chief Scientific Officer, MSK Direct  
Associate Attending, Department of Medicine

**LUKE R.G. PIKE, MD, DPHIL**

Assistant Attending, Department of Radiation Oncology

**PEDRAM RAZAVI, MD, PHD**

Director of Liquid Biopsy Technologies and Genomics  
Assistant Attending, Department of Medicine

**GREGORY J. RIELY, MD, PHD**

Vice Chair of Clinical Research  
Attending, Department of Medicine

**ANDREW D. SEIDMAN, MD**

Attending, Department of Medicine

**VIVIANE TABAR, MD**

Chair, Department of Neurosurgery  
Theresa Feng Chair in Neurosurgical Oncology

**JESSICA A. WILCOX, MD**

Assistant Attending, Department of Neurology

**RANDY YEH, MD**

Assistant Attending, Department of Radiology

**ROBERT J. YOUNG, MD**

Director, 3T Neuroradiology Imaging  
Attending, Department of Radiology

**MITIGATION OF  
RELEVANT FINANCIAL  
RELATIONSHIPS**

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

# Schedule

All times listed are Eastern Standard Time (EST).

7:45 AM	Attendee Zoom Sign On
7:55 AM	<b>Welcoming Remarks</b> Viviane Tabar, MD
8:00 AM	<b>Symposium Introduction</b> Nelson Moss, MD

## Brain Metastasis Challenges and Future Care Paradigms: Identifying and Validating Emerging Targets – Molecular Lenses

MODERATOR: Nelson Moss, MD

8:05 AM	<b>Expanding the Druggable Universe in Lung Cancer</b> Bob T. Li, MD, PhD, MPH
8:25 AM	<b>Identification of Therapeutic Targets in Brain Metastases: Targeting the CDK Signaling Pathway</b> Priscilla Brastianos, MD
8:45 AM	<b>Panel Discussion/Q&amp;A</b>

## Brain Met Prognosis 2023 (Changing Primary + BrM-specific Outlooks) – Disease Lenses

MODERATOR: Adrienne A. Boire, MD, PhD

8:50 AM	<b>Slowly but Surely: The Improving Prognosis of Patients With Breast Cancer Brain Metastases Related to Systemic Therapies</b> Sarah Sammons, MD
9:05 AM	<b>Lung Cancer</b> Gregory J. Riely, MD, PhD
9:20 AM	<b>Evolving Therapeutic Landscape, Outcomes and Prognostic Factors for Melanoma CNS Disease</b> Michael Davies, MD, PhD
9:35 AM	<b>Panel Discussion/Q&amp;A</b>

## What's New in Local Therapy and Post-RT Recurrence Salvage

MODERATOR: Nelson Moss, MD

9:40 AM	<b>Brain Metastases: The LITT Fit</b> Peter Fecci, MD
9:55 AM	<b>Brachytherapy for Post-radiation Salvage</b> Nelson Moss, MD Brandon Imber, MD, MA
10:10 AM	<b>Innovations in Brain Metastasis Radiation and Salvage</b> Kathryn Beal, MD
10:25 AM	<b>Panel Discussion/Q&amp;A</b>
10:30 AM	Break

---

## Translational and Trial Frontiers

MODERATOR: Adrienne A. Boire, MD, PhD

10:50 AM	<b>Strategies to Challenge Brain Metastasis Lethality in Mice and Humans</b> Manuel Valiente, PhD
11:05 AM	<b>Single Cell Analysis of Brain Metastasis</b> Min Yu, MD, PhD
11:20 AM	<b>Interferon Gamma Signaling in Leptomeningeal Metastasis</b> Adrienne A. Boire, MD, PhD
11:35 AM	<b>Window of Opportunity Approaches to Advance Medical Therapies</b> Nelson Moss, MD
11:50 AM	<b>Roundtable: What's Needed to Advance? Registries, Model/Resource-Sharing</b>
12:00 PM	<b>Q&amp;A</b>
12:05 PM	Lunch Break

## The Best Treatment Is Prevention: Early Detection 2023

MODERATOR: Andrew D. Seidman, MD

1:00 PM	<b>Molecular Imaging: Is There a Role for Brain Metastasis Yet?</b> Randy Yeh, MD
1:15 PM	<b>Screening for CNS Metastases in Breast Cancer: Ready for Prime Time?</b> Andrew D. Seidman, MD
1:30 PM	<b>Liquid Biopsy: Actionability in the Pre-validation Era</b> Pedram Razavi, MD, PhD
1:45 PM	<b>Panel Discussion/Q&amp;A</b>

## ROUNDTABLE: Streamlining Complex Care – How Busy Centers Do It

MODERATOR: Nelson Moss, MD

1:55 PM	<b>Memorial Sloan Kettering</b> • Nelson Moss, MD
2:00 PM	<b>Duke</b> • Peter Fecci, MD
2:05 PM	<b>Building a Translational CNS Metastasis Center: The MGH Experience</b> • Priscilla Brastianos, MD
2:10 PM	<b>Yale</b> • Veronica Chiang, MD
2:15 PM	<b>MD Anderson Cancer Center</b> • Hussein Tawbi, MD, PhD
2:20 PM	<b>Roundtable Discussion/Q&amp;A: Best Practices/Areas for Improvement</b>

---

## KEY CONTROVERSIES

MODERATOR: Adrienne A. Boire, MD, PhD

2:25 PM	<b>When to Change Therapy With CNS-Only Progression: Breast Cancer Perspective</b> Nancy Lin, MD
2:40 PM	<b>How Strongly Should Steroids Be Avoided - Impact on Immunotherapy Efficacy and Role of Concurrent RT</b> Hussein Tawbi, MD, PhD

2:55 PM	<b>Advanced Imaging of Growing Enhancing Lesions: Distinguishing Recurrent Metastases From Evolving Treatment Related Changes</b> Robert J. Young, MD
3:10 PM	<b>What LMD Interventions Are Worthwhile in 2023?</b> Adrienne A. Boire, MD, PhD
3:25 PM	<b>Panel Discussion/Q&amp;A</b>
3:35 PM	Break
<b>MULTIDISCIPLINARY TUMOR BOARD</b>	
3:45 PM	Nelson Moss, MD Jessica A. Wilcox, MD Luke R.G. Pike, MD, DPhil Bob T. Li, MD, PhD, MPH Andrew D. Seidman, MD Robert J. Young, MD
4:45 PM	<b>Closing Remarks</b> Nelson Moss, MD
5:00 PM	Adjourn

### Educational Objectives

At the completion of this program, learners will be able to:

- Describe the current multimodal landscape of brain metastasis treatment
- Identify key clinical controversies in brain metastasis management
- Discuss barriers to improved treatments and potential research strategies (e.g. limited CNS activity of systemic anti-cancer treatments, side effects of local treatments, limited survival, and unclear endpoints)

### Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **6.75 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.





# Register for free: [mskcc.org/BrainMetsSymposium](https://mskcc.org/BrainMetsSymposium)

Please note that **registration is required** in order to participate in this Symposium.

This live virtual program will be **delivered using Zoom**. We encourage all attendees to download the Zoom app prior to the start of the course ([zoom.us/download](https://zoom.us/download)). CME credit will be offered for this live virtual program.

Detailed **access instructions will be emailed to registered attendees prior to the start** of the program.

If you are registered for this symposium and unable to attend, please email [cme@mskcc.org](mailto:cme@mskcc.org) to cancel your registration.

**Industry professionals** may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities. For more information, please visit our [Help](#)



Memorial Sloan Kettering  
Cancer Center